hk-ipo/data/extracted_text/02335/allotment_results_2026-06-23_2026062301227.txt

--- page 1 ---
– 1 –
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “ Stock
Exchange ”) and Hong Kong Securities Clearing Company Limited (“ HKSCC ”) take no responsibility for the
contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim
any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States
(including its territories and possessions, any state of the United States and the District of Columbia) or any
other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a
part of any offer to sell or solicitation of an offer to buy, to purchase or subscribe for securities nor shall there
be any sale of Offer Shares in the United States or in any other jurisdictions in which such offer or solicitation
would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United
States Securities Act of 1933 as amended from time to time (the “ U.S. Securities Act ”) or any state securities
law of the United States. The securities may not be offered, sold, pledged, or transferred within the United
States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities
Act (“ Regulation S ”)) except pursuant to an exemption from, or in a transaction not subject to, the registration
requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will
be no public offering of securities in the United States. The Offer Shares are being offered and sold outside the
United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an invitation or offer to acquire,
purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential
investors should read the prospectus dated June 15, 2026 (the “ Prospectus ”) of Shaanxi Micot Pharmaceutical
Technology Co., Ltd. (
ʮ̡ ) (the “ Company ”) carefully for detailed
information about the Company and  the Global Offering before deciding whether or not to  invest in the Offer
Shares. Any investment decision in relation to the Global Offering should be taken solely in reliance on the
information in the Prospectus.
Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as
those defined in the Prospectus.
In connection with the Global Offering, CCB International Capital Limited, as the stabilizing manager (the
“Stabilizing Manager ”), its affiliates or any person acting for it, may, to the extent permitted by applicable
laws of Hong Kong or elsewhere, over-allocate or effect transactions with a view to stabilizing or maintaining
the market price of the Shares at a level higher than that which might otherwise prevail for a limited period
after the Listing Date. However, there is no obligation on the Stabilizing Manager (its affiliates or any person
acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at
the absolute discretion of the Stabilizing Manager (its affiliates or any person acting for it) and in what the
Stabilizing Manager reasonably regards as the best interest of the Company, (b) may be discontinued at any
time and (c) is required to be brought to an end within 30 days of the last day for lodging applications under the
Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it
is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements,
including the Securities  and Futures (Price  Stabilizing) Rules (Cha pter 571W of the Laws of Hong Kong), as
amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).
Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for
longer than the stabilization period will begin on the Listing Date, and is expected to expire on Saturday, July
18, 2026, the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.
After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the
Shares, could fall.
The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions
set out in the Prospectus. The Hong Kong Offer Shares will  not be offered to any person who is outside Hong
Kong and/or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Overall
Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their
obligations under the Hong Kong Underwriting Agreement upon the occurrence of any of the events set out in the
paragraph headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering
— Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing
Date (which is currently expected to be Wednesday, June 24, 2026).


--- page 2 ---
– 2 –
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
ʮ̡
(A joint stock company incorporated in the People’s Republic of China with limited liability)
GLOBAL OFFERING
Number of Offer Shares under the
Global Offering
: 58,054,400 H Shares
Number of Hong Kong Offer Shares : 5,805,600 H Shares
Number of International Offer Shares : 52,248,800 H Shares
Final Offer Price : HK$18.20 per H Share, plus brokerage
of 1.0%, SFC transaction levy of
0.0027%, AFRC transaction levy of
0.00015% and the Stock Exchange
trading fee of 0.00565% (payable in full
on application in Hong Kong Dollars,
subject to refund)
Nominal value : RMB0.02 per H Share
Stock code : 2335
Joint Sponsors, Overall Coordinators, Sponsor-Overall Coordinators,
Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers
Joint Bookrunners and Joint Lead Managers
SOMERLEY CAPITAL LIMITED
⳪暲@:9)


--- page 3 ---
– 3 –
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
ʮ̡
ANNOUNCEMENT OF ALLOTMENT RESULTS
Warning: In view of high concentration of shareholding in a small number of H
Shareholders, Shareholders and prospective investors should be aware that the price
of the H Shares could move substantially even with a small number of H Shares
traded and should exercise extreme caution when dealing in the H Shares.
SUMMARY
Company information
Stock code 2335
Stock short name MICOT PHARMA-B
Dealings commencement date June 24, 2026 *
* see note at the end of the announcement
Price Information
Final Offer Price HK$18.20
Offer Shares and Share Capital
Number of Offer Shares 58,054,400
Final number of Offer Shares in Hong Kong Public
Offering
5,805,600
Final number of Offer Shares in International
Offering
52,248,800
Number of issued Shares upon Listing 331,740,350
Over-allocation
No. of Offer Shares over-allocated 0
There has been no over-allocation of Offer Shares in the International Offering.
Therefore, the Over-allotment Option will not be exercised and will lapse upon Listing.
Proceeds
Gross proceeds (Note) HK$1,056.6 million
Less: Estimated listing expenses payable based on
Final Offer Price
HK$67.3 million
Net proceeds HK$989.3 million


--- page 4 ---
– 4 –
Note: Gross proceeds refer to the amount which the Company is entitled to receive. For details of the use of
proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus.
ALLOTMENT RESULTS DETAILS
HONG KONG PUBLIC OFFERING
No. of valid applications 153,832
No. of successful applications 22,665
Subscription level 1,181.46 times
Claw-back triggered N/A
No. of Offer Shares initially available under the Hong
Kong Public Offering
5,805,600
No. of Offer Shares reallocated from the International
Offering
0
Final no. of Offer Shares under the Hong Kong Public
Offering
5,805,600
% of Offer Shares under the Hong Kong Public Offering
to the Global Offering
10%
Note: For details of the final allocation  of H Shares to the Hong Kong  Public Offering, investors can refer to
www.hkeipo.hk/IPOResult to perform a search by identification document number or www.hkeipo.hk/IPOResult
for the full list of allottees.
INTERNATIONAL OFFERING
No. of placees 73
Subscription Level 2.52 times
No. of Offer Shares initially available under the
International Offering
52,248,800
No. of Offer Shares reallocated to the Hong Kong
Public Offering
0
Final no. of Offer Shares under the International
Offering
52,248,800
% of Offer Shares under the International Offering to
the Global Offering
90%
The Directors confirm that, to the best of their knowledge, information and belief, save for
consent under paragraph 1C (2) of Appendix F1 to the Listing Rules granted by the Stock
Exchange to permit Qiyuan Hong Kong, a close associates of Existing Shareholders, to


--- page 5 ---
– 5 –
participate in the Global Offering as a cornerstone investor subject to certain conditions,
(i) none of the Offer Shares subscribed by the placees and the public have been financed
directly or indirectly by the Company, any of the Directors, chief executive of the Company,
Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company
or any of its subsidiaries or their respective close associates; and (ii) none of the placees and
the public who have purchased the Offer Shares are accustomed to taking instructions from
the Company, any of the Directors, chief executive of the Company, Controlling Shareholders,
substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries
or their respective close associates in relation to the acquisition, disposal, voting or other
disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.
The placees in the International Offering include the following:
Cornerstone Investors
Investor note 1
TNo. of Offer Shares
allocated
% of Offer Shares
after the Global
Offering
% of total issued
share capital in the
Company after the
Global Offering
Existing
shareholders or
their close
associates
Qiyuan Hong Kong note 2 18,756,200 32.31% 5.65% YES
Everest Medicine 5,494,400 9.46% 1.66% No
Summit Capital 430,400 0.74% 0.13% No
Total 24,681,000 42.51% 7.44%
Notes:
1. For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone
Investors” in the Prospectus.
2. As disclosed in the Prospectus, as Qiyuan Hong Kong is ultimately controlled by government bodies
of Shaanxi Province, it is a close associate of existing Shareholders of the Company. The Company
has sought, and the Stock Exchange has given, a consent under paragraph 1C (2) of Appendix F1 to
the Listing Rules to permit Qiyuan Hong Kong to participate in the Global Offering as a cornerstone
investor subject to certain conditions. For further details of the abovementioned consent, please refer
to the section headed “Waivers from Strict Compliance with the Listing Rules and Exemption from
Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance” in the
Prospectus and “Others/Additional Information” in this announcement for details.


--- page 6 ---
– 6 –
Allottee with Waiver/Consent Obtained
Investor
No. of Offer
Shares allocated
% of Offer Shares
after the Global
Offering Note 4
% of total issued
share capital in the
Company after the
Global Offering Note 5 Relationship
Allottee with consent under paragraph 1C (2) of the Placing Guidelines under Chapters 2.3 and 4.15 of the
Guide in relation to allocation of Offer Shares to a close associate of existing Shareholders Note 1
Qiyuan Hong Kong 18,756,200 32.31% 5.65% A close associate
of existing
Shareholders
Notes:
1. The Stock Exchange has given a consent under paragraph 1C(2) of the Placing Guidelines and Chapters 2.3 and 4.15 of Guide to
permit Offer Shares to be placed to the above placee who is a close associate of existing Shareholders. Please refer to the sec tion
headed “Others/Additional Information” in this announcement.


--- page 7 ---
– 7 –
LOCK-UP UNDERTAKINGS
Cornerstone Investors
Name
Number of Shares
held in the Company
subject to lock-up
undertakings upon
Listing
% of total issued
H Shares after the
Global Offering
subject to lock-up
undertakings upon
Listing
% of total issued
share capital in
the Company
subject to lock-up
undertakings upon
Listing
Last day subject
to the lock-up
undertakings Note 1
Qiyuan Hong Kong 18,756,200 6.70% 5.65% December 23, 2026
Everest Medicine 5,494,400 1.96% 1.66% December 23, 2026
Summit Capital 430,400 0.15% 0.13% December 23, 2026
Total 24,681,000 8.81% 7.44%
Notes:
1. In accordance with the relevant cornerstone investment agreements, the required lock-up ends on December 23, 2026. The
Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed pursuant to the relevan t
cornerstone investment agreements after the indicated date.
Controlling Shareholders
Name Note 1
Number of Shares held
in the Company subject
to lock-up undertakings
upon Listing
Number of H Shares
held in the Company
subject to lock-up
undertakings upon
Listing
% of total issued H
Shares after the Global
Offering subject to
lock-up undertakings
upon Listing
% of total issued share
capital in the Company
subject to lock-up
undertakings upon
Listing
Last day subject to
the lock-up
undertakings Note 2
Dr. Wang Bing 111,000,000 66,600,000 23.78% 33.46% June 23, 2027
Dr. Wang Mei 18,060,050 18,060,050 6.45% 5.44% June 23, 2027
Xi’an Zhongrui 15,000,000 15,000,000 5.36% 4.52% June 23, 2027
Total 144,060,050 99,660,050 35.58% 43.43%
Notes:
1. As of the date of this announcement, Dr. Wang Bing ( ˮΏ ), Dr. Wang Mei ( ˮૠ ) and Xi’an Zhongrui directly held 40.56%, 6.60% and 5.48% of the interest in our Company, respectively.
Dr. Wang Bing and Dr. Wang Mei are spouses. Dr. Wang Mei and Dr. Wang Bing held 99.00% and 1.00% of the equity interest, respec tively, in Zhongrui Zekang, which acts as the general
partner of Xi’an Zhongrui. Xi’an Zhongrui directly held 5.48% of the equity interest in the Company, such that Dr. Wang Mei and  Dr. Wang Bing are deemed to be the beneficial owners
of the 5.48% equity interest in the Company held by Xi’an Zhongrui. Therefore, Dr. Wang Bing, Dr. Wang Mei, Xi’an Zhongrui and Zhongrui Zekang will be regarded as our Controlling
Shareholders under the Listing Rules before the Listing. For further details, please refer to the section headed “Relationship with our Controlling Shareholders” in the Prospectus.
2. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. The required lock-up for the Controlling Shareholders ends on June 23, 2027, being
twelve months following the Listing Date. Pursuant to Rule 10.07 of the Listing Rules, each of the Controlling Shareholders (na mely Dr. Wang Bing, Dr. Wang Mei, Xi’an Zhongrui and
Zhongrui Zekang) has undertaken to the Stock Exchange and the Company that, he, she or it shall comply with the applicable lock up requirements. For further details, please refer to the
section headed “Underwriting — Undertakings to the Stock Exchange Pursuant to the Listing Rules — Undertakings by our Controlli ng Shareholders” in the Prospectus.


--- page 8 ---
– 8 –
Other Existing Shareholders
Name
Number of Shares held
in the Company subject
to lock-up undertakings
upon Listing
Number of H Shares
held in the Company
subject to lock-up
undertakings
upon Listing
% of total issued H
Shares after the Global
Offering subject to
lock-up undertakings
upon Listing
% of total issued share
capital in the Company
subject to lock-up
undertakings upon
Listing
Last day subject to
the lock-up
undertakings Note 1
The People’s Government of Shaanxi Province
Junying Growth 3,982,350 3,982,350 1.42% 1.20% June 23, 2027
Listing Reserve Fund 3,631,750 3,631,750 1.30% 1.09% June 23, 2027
Junying Jiacheng 2,017,650 2,017,650 0.72% 0.61% June 23, 2027
Xi’an Huiyu 907,950 907,950 0.32% 0.27% June 23, 2027
Shaanxi Innovation Relay 4,153,850 – – 1.25% –
Shaanxi Jingang 3,115,400 – – 0.94% –
New Materials Fund 6,000,000 6,000,000 2.14% 1.81% June 23, 2027
Other Shareholders
Suzhou Mainiv 27,333,350 27,333,350 9.76% 8.24% June 23, 2027
Beta Achieve 17,733,350 17,733,350 6.33% 5.35% June 23, 2027
Linhai Qize 14,382,650 14,382,650 5.14% 4.34% June 23, 2027
Huaxin Pharmaceutical Venture
Capital 7,776,650 7,776,650 2.78% 2.34% June 23, 2027
Suzhou Rongsheng 6,833,350 6,833,350 2.44% 2.06% June 23, 2027
Xi’an Tongshang 5,939,950 5,939,950 2.12% 1.79% June 23, 2027
Fengchuan Hongbo 5,125,000 5,125,000 1.83% 1.54% June 23, 2027
Jingcheng Daxing 5,075,100 5,075,100 1.81% 1.53% June 23, 2027
Tangxing Technology 4,780,200 4,780,200 1.71% 1.44% June 23, 2027
Shanjin Runji 3,947,750 3,947,750 1.41% 1.19% June 23, 2027
Hainan Wanfeng 1,361,900 1,361,900 0.49% 0.41% June 23, 2027
Yinyun Heman 907,950 907,950 0.32% 0.27% June 23, 2027
Hangzhou Quandewang 907,950 907,950 0.32% 0.27% June 23, 2027
Hainan Ruizheng 907,950 907,950 0.32% 0.27% June 23, 2027


--- page 9 ---
– 9 –
Name
Number of Shares held
in the Company subject
to lock-up undertakings
upon Listing
Number of H Shares
held in the Company
subject to lock-up
undertakings
upon Listing
% of total issued H
Shares after the Global
Offering subject to
lock-up undertakings
upon Listing
% of total issued share
capital in the Company
subject to lock-up
undertakings upon
Listing
Last day subject to
the lock-up
undertakings Note 1
Maicheng Century 1,557,700 1,557,700 0.56% 0.47% June 23, 2027
Jinan Liuji 1,246,150 1,246,150 0.44% 0.38% June 23, 2027
Total 129,625,900 122,356,650 43.69% 39.07%
Notes:
1. Under the applicable PRC laws, all existing Shareholders are subject to a lockup period of twelve months following the Listi ng Date.
PLACEE CONCENTRATION ANALYSIS
Placees*
Number of
H Shares
allotted
Allotment as
% of
International
Offering
Allotment as
% of total
Offer Shares
Number of
H Shares held
upon Listing
% of total
issued share
capital upon
Listing
Top 1 18,756,200 35.90% 32.31% 18,756,200 5.65%
Top 5 39,640,000 75.87% 68.28% 39,640,000 11.95%
Top 10 45,269,000 86.64% 77.98% 45,269,000 13.65%
Top 25 51,790,600 99.12% 89.21% 51,790,600 15.61%
Note:
* Ranking of placees is based on the number of H Shares allotted to the placees.


--- page 10 ---
– 10 –
H SHAREHOLDER CONCENTRATION ANALYSIS
H Shareholders*
Number of
H Shares
allotted
Allotment as
% of
International
Offering
Allotment
as % of total
Offer Shares
Number of
H Shares held
upon Listing
% of total
issued
H share
capital upon
Listing
Number of
Shares held
upon Listing
Top 1 0 NA NA 99,660,050 35.58% 144,060,050
Top 5 18,756,000 35.90% 32.31% 194,405,300 69.41% 246,074,550
Top 10 33,204,000 63.55% 57.20% 229,403,650 81.91% 281,072,900
Top 25 44,574,800 85.31% 76.78% 265,683,550 94.86% 317,352,800
Note:
* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.
SHAREHOLDER CONCENTRATION ANALYSIS
Shareholders*
Number of
H Shares
allotted
Allotment
as % of
International
Offering
Allotment as
% of total
Offer Shares
Number of
H Shares held
upon Listing
Number of
Shares held
upon Listing
% of total
issued share
capital upon
Listing
Top 1 0 NA NA 99,660,050 144,060,050 43.43%
Top 5 18,756,200 35.90% 32.31% 194,405,300 246,074,550 73.18%
Top 10 33,204,600 63.55% 57.20% 229,403,650 281,072,900 84.73%
Top 25 44,574,800 85.31% 76.78% 265,683,550 317,352,800 95.66%
Note:
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholders upon
Listing.


--- page 11 ---
– 11 –
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
Subject to the satisfaction of the conditions set out in the Prospectus, a total of 153,832 valid
applications made by the public will be conditionally allocated on the basis set out below:
Pool A
Number of
H Shares
applied for
Number of
valid
applications Basis of allocation/ballot
Approximate
percentage
allotted
of the total
number of
H Shares
applied for
200 44,060 1,322 out of 44,060 applicants to receive 200 H Shares 3.00%
400 24,701 976 out of 24,701 applicants to receive 200 H Shares 1.98%
600 4,048 188 out of 4,048 applicants to receive 200 H Shares 1.55%
800 2,703 141 out of 2,703 applicants to receive 200 H Shares 1.30%
1,000 3,083 175 out of 3,083 applicants to receive 200 H Shares 1.14%
1,200 1,918 118 out of 1,918 applicants to receive 200 H Shares 1.03%
1,400 1,344 88 out of 1,344 applicants to receive 200 H Shares 0.94%
1,600 1,425 98 out of 1,425 applicants to receive 200 H Shares 0.86%
1,800 1,500 108 out of 1,500 applicants to receive 200 H Shares 0.80%
2,000 12,982 970 out of 12,982 applicants to receive 200 H Shares 0.75%
3,000 3,436 302 out of 3,436 applicants to receive 200 H Shares 0.59%
4,000 4,863 479 out of 4,863 applicants to receive 200 H Shares 0.49%
5,000 1,990 214 out of 1,990 applicants to receive 200 H Shares 0.43%
6,000 1,481 171 out of 1,481 applicants to receive 200 H Shares 0.38%
7,000 1,130 139 out of 1,130 applicants to receive 200 H Shares 0.35%
8,000 1,070 139 out of 1,070 applicants to receive 200 H Shares 0.32%
9,000 1,558 212 out of 1,558 applicants to receive 200 H Shares 0.30%
10,000 6,201 877 out of 6,201 applicants to receive 200 H Shares 0.28%
20,000 5,421 1,009 out of 5,421 applicants to receive 200 H Shares 0.19%
30,000 3,691 807 out of 3,691 applicants to receive 200 H Shares 0.15%
40,000 2,469 605 out of 2,469 applicants to receive 200 H Shares 0.12%
50,000 1,567 420 out of 1,567 applicants to receive 200 H Shares 0.11%
60,000 1,352 389 out of 1,352 applicants to receive 200 H Shares 0.10%
70,000 1,071 328 out of 1,071 applicants to receive 200 H Shares 0.09%
80,000 750 242 out of 750 applicants to receive 200 H Shares 0.08%
90,000 647 219 out of 647 applicants to receive 200 H Shares 0.08%
100,000 4,429 1,559 out of 4,429 applicants to receive 200 H Shares 0.07%
200,000 4,791 2,219 out of 4,791 applicants to receive 200 H Shares 0.05%

Total 145,681 Total number of Pool A successful applicants: 14,514


--- page 12 ---
– 12 –
Pool B
Number of
H Shares
applied for
Number of
valid
applications Basis of allocations/ballot
Approximate
percentage
allotted
of the total
number of
H Shares
applied for
300,000 4,433 200 H Shares plus 2,217 out of 4,433 applicants to
receive an additional 200 H Shares
0.10%
400,000 912 200 H Shares plus 609 out of 912 applicants to
receive an additional 200 H Shares
0.08%
500,000 725 200 H Shares plus 588 out of 725 applicants to
receive an additional 200 H Shares
0.07%
600,000 348 200 H Shares plus 326 out of 348 applicants to
receive an additional 200 H Shares
0.06%
700,000 339 400 H Shares 0.06%
800,000 204 400 H Shares plus 32 out of 204 applicants to
receive an additional 200 H Shares
0.05%
900,000 123 400 H Shares plus 31 out of 123 applicants to
receive an additional 200 H Shares
0.05%
1,000,000 618 400 H Shares plus 209 out of 618 applicants to
receive an additional 200 H Shares
0.05%
2,000,000 126 600 H Shares 0.03%
2,902,800 323 600 H Shares plus 169 out of 323 applicants to
receive an additional 200 H Shares
0.02%

Total 8,151 Total number of Pool B successful applicants: 8,151
As of the date of this announcement, the relevant subscription monies previously deposited
in the designated nominee accounts have been remitted back to the accounts of all HKSCC
participants. Investors should contact their relevant brokers for any inquiries.
COMPLIANCE WITH LISTING RULES AND GUIDANCE
The Directors confirm that, except for the Listing Rules that have been waived and/or in
respect of which consent has been obtained, the Company has complied with the Listing Rules
and guidance materials in relation to the placing, allotment and listing of the Company’s H
Shares.
The Directors confirm that, to the best of their knowledge, the consideration paid by
the placees or the public (as the case may be) directly or indirectly for each Offer Share
subscribed for or purchased by them was the same as the final Offer Price in addition to any
brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee
payable.


--- page 13 ---
– 13 –
OTHERS/ADDITIONAL INFORMATION
Allocation of Offer Shares to a Close Associate of the Existing Shareholders
The Company has sought, and the Stock Exchange has given, a consent under the paragraph
1C(2) of Appendix F1 to the Listing Rules to permit Qiyuan Hong Kong to participate in the
Global Offering as a cornerstone investor subject to the conditions that:
(a) our Company will comply with the public float requirements of Rule 19A .13A and
the free float requirement under Rule 19A.13C of the Listing  Rules. For details  of the
calculation of public float and free float of the Company, please refer to the section
headed “History, Development and Corporate Structure” in this prospectus;
(b) the Offer Shares to be subscribed by and allocated to Qiyuan Hong Kong as a
Cornerstone Investor under the Global Offering will be at the same Offer Price and on
substantially the same terms as the other Cornerstone Investors (including being subject
to a lock-up period of six months from the Listing Date, and Qiyuan Hong Kong shall
pay and settle in full the consideration for the Offer Shares before the dealing commence
on the Listing Date);
(c) no preference in allocation has been, nor will be, given to Qiyuan Hong Kong other than
the preferential treatment of assured entitlement at  the Offer Price under a cornerstone
investment and the terms of the cornerstone investment agreement of the Qiyuan
Hong Kong are substantially the same as the other cornerstone investment agreements
following the principles set  out in Chapters 2.3 and  4.15 of the Guide and each of the
Company, the Joint Sponsors and the Overall Coordinators has provided the Stock
Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the
Guide for New Listing Applicants; and
(d) details of the allocation of the Offer Shares to Qiyuan Hong Kong in the Global Offering
as a cornerstone investor are disclosed in this prospectus, and details of the allocation
will be disclosed in the allotment results announcement of our Company.
Such allocations of Offer Shares to Qiyuan Hong Kong, as the close associate of the Existing
Shareholders is in compliance with all the conditions under the consent given by the Stock
Exchange.
For details of the allocations of Offer Shares to Qiyuan Hong Kong, please refer to the section
headed “Allotment Results Details — International Offering — Cornerstone Investors” in this
announcement.


--- page 14 ---
– 14 –
DISCLAIMERS
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited
and Hong Kong Securities Clearing Company Limited take no responsibility for the
contents of this announcement, make no representation as to its accuracy or completeness
and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in
or into the United States (including its territories and possessions, any state of the United
States and the District of Columbia) or any other jurisdiction where such distribution is
prohibited by law. This announcement does not constitute or form a part of any offer to sell
or solicitation of an offer to buy, to purchase or subscribe for securities nor shall there be
any sale of Offer Shares in the United States or in any other jurisdictions in which such
offer or solicitation would be unlawful. The securities mentioned herein have not been,
and will not be, registered under the United States Securities Act or any state securities
law of the United States. The securities may not be offered, sold, pledged, or transferred
within the United States or to, or for the account or benefit of U.S. persons (as defined in
Regulation S) except pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the U.S. Securities Act and in compliance with any applicable
state securities laws. The Offer Shares are being offered and sold outside the United States
in offshore transactions in reliance on Regulation S under the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an invitation or
offer to acquire, purchase or subscribe for securities of the Company. This announcement is
not a prospectus. Potential investors should read the Prospectus dated June 15, 2026 issued
by Shaanxi Micot Pharmaceutical Technology Co., Ltd. (
ࠢ
ʮ̡ ) for detailed information about the Global Offering described below before deciding
whether or not to invest in the Offer Shares.
* Potential investors of the Offer Shares should note that the Overall Coordinators (for
themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate
their obligations under the Hong Kong Underwriting Agreement upon the occurrence of any
of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements
and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus
at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently
expected to be Friday, June 24, 2026).
PUBLIC FLOAT AND FREE FLOAT
Rule 19A.13A of the Listing Rules requires that where the expected market value of the Shares
at the time of Listing  is over HK $6,000,000,000 but not  exceeding HK $30,000,000,000, the
minimum prescribed percentage of the Shares which must be H Shares held by the public is
determined at the higher of: (i) the percentage that would result in the expected market value
of the H Shares held by the public to be HK $1,500,000,000 at the time of Listing; and (ii)
15%.


--- page 15 ---
– 15 –
Immediately after the completion of the Global Offering, an aggregate of 145,115,150 H
Shares, representing approximately 43.74% of the total issued share capital of the Company
upon the completion of the Global Offering will be counted towards the public float. Based
on the Offer Price of HK $18.20 per Offer Share, the expected market capitalization of the
Company’s H Shares would exceed HK$6,000,000,000 and the percentage that would result in
the expected market value of H shares held by the public to be HK$1,500,000,000 at the time
of Listing would be 24.84%. Therefore, the Company will be able to meet the public float
requirement under Rule 19A.13A of the Listing Rules.
Rule 19A.13C(1) of the  Listing Rules provides that,  where a new applicant is a PRC issuer
with no other listed shares at the time of listing, the portion of H shares for which listing is
sought that are held by the public and not subject to any disposal restrictions at the time listing
must normally (i) represent at least 10% of the total number of issued shares in the class to
which H shares belong at the time of listing (excluding treasury shares), with an expected
market value at the time of listing of not less than HK$50,000,000; or (ii) have an expected
market value at the time of listing of not less than HK$600,000,000.
Immediately after the completion of the Global Offering, based on the Offer Price of
HK$18.20, except for (i) 273,685,950 Shares held by all existing Shareholders that are
subject to a lock-up period of twelve months following the Listing Date under applicable PRC
law; and (ii) 24,681,000 Shares held by Cornerstone Investors that are subject to a lock-up
period of six months from  and including the Listing Date, all remaining  33,373,400 Shares,
representing 10.06% of the total Shares, will be counted toward the free float. Therefore, our
Company will be able to sa tisfy the free float requiremen t under Rule 19A.13C(1)(a) of the
Listing Rules.
COMMENCEMENT OF DEALINGS
The H Share certificates will only become valid evidence of title at 8:00 a.m. on Wednesday,
June 24, 2026 (Hong Kong time), provided that the Global Offering has become unconditional
and the right of termination described in  the section headed “Underwriting — Underwriting
Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination”
in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of
publicly available allocation details prior to the receipt of H Share certificates or prior to the
H Share certificates becoming valid evidence of title do so entirely at their own risk.


--- page 16 ---
– 16 –
Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on
Wednesday, June 24, 2026 (Hong Kong time), it is expected that dealings in the H Shares on
the Stock Exchange will commence at 9:00 a.m. on Wednesday, June 24, 2026 (Hong Kong
time). The H Shares will be traded in board lots of 200 H Shares each, and the stock code of
the H Shares will be 2335.
By order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director
Hong Kong, June 23, 2026
As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu
Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang
and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang
Wenqiang and Mr. Wang Kaifeng as proposed independent non-executive Directors.